Vietnam is currently witnessing an unprecedented transformation in its healthcare sector. As part of the government's "Strategy for Development of the Pharmaceutical Industry to 2030," there is a significant push toward domestic self-sufficiency and the procurement of high-tech biologicals. The Vietnam pharmaceutical market is projected to reach USD 16.1 billion by 2026, driven by an aging population, rising healthcare expenditure, and the expansion of the National Expanded Program on Immunization (EPI).
Navigating the Drug Administration of Vietnam (DAV) requires deep expertise. Our products strictly adhere to GMP-WHO standards, ensuring rapid registration and market entry for local distributors in Binh Duong and Ho Chi Minh City.
High demand exists for specialized treatments in traumatic care and infectious disease prevention. Products like Aceglutamide and Rabies Vaccines are critical for Vietnam’s frontline hospitals.
The rise of biopharmaceutical industrial parks in Vietnam creates a need for high-quality APIs and intermediates. We provide the "Information Gain" needed to optimize these supply chains.
China has emerged as the global leader in biopharmaceutical manufacturing capacity. For the Vietnam market, this translates to Cost-Efficiency, Supply Chain Resilience, and Technical Superiority. Our facilities utilize state-of-the-art bio-fermentation and co-crystallization technologies that meet BP/USP/EP standards.
Supplying municipal health centers in Hanoi and Da Nang with Rabies Vaccines. Our Vero cell technology ensures lower adverse reactions compared to older platforms, aligning with Vietnam's Ministry of Health safety mandates.
Vietnam’s climate necessitates robust malaria and infection control. Our Artesunate Tablets are specifically formatted for the rescue of cerebral malaria, a critical need in Vietnam’s central highlands.
In major surgical hubs like Cho Ray Hospital, the use of Aceglutamide for neuro-recovery following trauma is becoming a standard clinical protocol.
Urban populations in Ho Chi Minh City are increasingly seeking high-purity supplements. We supply NMNH (Reduced NMN) to local health brands looking for premium "Made in China" ingredients.
We don't just sell products; we provide End-to-End Biological Solutions. Our service model for Vietnam includes:
Optimizing API formulations for local Vietnamese pharmaceutical manufacturers to reduce production complexity.
Enhancing the solubility and stability of molecules like Metronidazole for better therapeutic outcomes.
Utilizing green chemistry to produce high-purity peptides and proteins with minimal environmental impact.
Under Circular 32/2018/TT-BYT, all biologicals imported into Vietnam must have a Certificate of Pharmaceutical Product (CPP) from the country of origin and proof of GMP compliance. Our team provides the full dossier support to ensure seamless approval by the DAV.
We utilize validated cold-chain logistics with real-time temperature monitoring. For products like the Rabies Vaccine, we maintain a strict 2°C to 8°C environment, preventing denaturation and ensuring efficacy upon arrival at Vietnamese medical facilities.
China accounts for over 20% of the world’s API production. By sourcing from Jiangxi Serum Pharma, Vietnamese buyers benefit from direct factory pricing, massive production capacity that avoids stockouts, and compliance with USP/BP pharmacopeia standards that are widely accepted in Vietnam.
Yes, we offer products like Fava Bean Protein and Walnut Peptide, which cater to the growing demand for clean-label, vegan-friendly nutritional solutions in urban Vietnam.
Join over 500 global clients who trust Jiangxi Serum Pharma for pharmaceutical excellence and industrial-grade reliability.
Send Inquiry Now & Get Expert Consultation
